Biotechnology
BioMarin Pharmaceutical Inc. BMRN announced that the FDA has issued a complete response letter (CRL) to its biologics license application (BLA) for Roctavian (valoctocogene roxaparvovec/valrox), an investigational gene therapy, developed for treating patients with severe hemophilia ... [Read]